Pharmaceuticals (May 2023)

<i>RYK</i> Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients

  • Ricardo D. Gonzalez,
  • George W. Small,
  • Adrian J. Green,
  • Farida S. Akhtari,
  • Tammy M. Havener,
  • Julia C. F. Quintanilha,
  • Amber B. Cipriani,
  • David M. Reif,
  • Howard L. McLeod,
  • Alison A. Motsinger-Reif,
  • Tim Wiltshire

DOI
https://doi.org/10.3390/ph16050726
Journal volume & issue
Vol. 16, no. 5
p. 726

Abstract

Read online

Temozolomide (TMZ) chemotherapy is an important tool in the treatment of glioma brain tumors. However, variable patient response and chemo-resistance remain exceptionally challenging. Our previous genome-wide association study (GWAS) identified a suggestively significant association of SNP rs4470517 in the RYK (receptor-like kinase) gene with TMZ drug response. Functional validation of RYK using lymphocytes and glioma cell lines resulted in gene expression analysis indicating differences in expression status between genotypes of the cell lines and TMZ dose response. We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of RYK gene expression status on glioma patient overall (OS) and progression-free survival (PFS). Our results indicated that in IDH mutant gliomas, RYK expression and tumor grade were significant predictors of survival. In IDH wildtype glioblastomas (GBM), MGMT status was the only significant predictor. Despite this result, we revealed a potential benefit of RYK expression in IDH wildtype GBM patients. We found that a combination of RYK expression and MGMT status could serve as an additional biomarker for improved survival. Overall, our findings suggest that RYK expression may serve as an important prognostic or predictor of TMZ response and survival for glioma patients.

Keywords